<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04175197</url>
  </required_header>
  <id_info>
    <org_study_id>LEGDEB2 v.3.1</org_study_id>
    <nct_id>NCT04175197</nct_id>
  </id_info>
  <brief_title>LegDeb2 Global Registry for Use of Legflow in Peripheral Arteries</brief_title>
  <acronym>LEGDEB2</acronym>
  <official_title>The LegDeb2 Global Registry for the Treatment of Superficial Femoral, Popliteal or Below-The-Knee Artery Lesions Using the Legflow DrugEluting Balloon</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Federico II University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Federico II University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      LEGDEB2 is a Global Registry for the Treatment of Superficial Femoral and/or Popliteal or
      Below-The-Knee or Iliac Artery Lesions Using the Legflow Drug-Eluting Balloon
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      LEGDEB2 is a Global Registry aimed to prospectively collect and assess global safety and
      efficacy data on the Legflow Drug Eluting Balloon (DEB) in treatment of atherosclerotic
      disease of the superficial femoral and/or popliteal and/or below-the-knee and/or iliac
      arteries in &quot;real world&quot; patient population.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 2019</start_date>
  <completion_date type="Anticipated">December 2024</completion_date>
  <primary_completion_date type="Anticipated">December 2024</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Efficacy: Freedom from Clinically driven TLR</measure>
    <time_frame>12 Months</time_frame>
    <description>Freedom from clinically-driven target lesion revascularization (TLR) within 12 months post-index procedure, which is defined as:
Any re-intervention within the target lesion(s) due to symptoms</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety: Freedom from MAE</measure>
    <time_frame>30 days</time_frame>
    <description>A composite of freedom from device- and procedure-related mortality through 30 days, freedom from device or procedure related mortality, freedom from any cardiac or cardiovascular death, freedom from major target limb amputation</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Freedom from MALE and MACCE</measure>
    <time_frame>30 days, 6 Months, 12 Months, 24 Months, 36 Months</time_frame>
    <description>MALE is defined as acute limb ischemia, urgent revascularization or mayor amputation of the treated limb MACCE is defined as Death, Acute myocardial infarction or stroke</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Freedom from all cause mortality</measure>
    <time_frame>30 days, 6 Months, 12 Months, 24 Months, 36 Months</time_frame>
    <description>all cause mortaliy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Freedom from CD-TLR</measure>
    <time_frame>24 Months, 36 Months</time_frame>
    <description>Clinically driven Target Lesion Revascularization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Freedom from CD-TVR</measure>
    <time_frame>6 Months, 12 Months, 24 Months, 36 Months</time_frame>
    <description>Clinically driven Target Vessel Revascularization Clinically-driven TVR is defined as any re-intervention within the target vessel due to symptoms</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Freedom from Major target limb amputation</measure>
    <time_frame>30 days, 6 Months, 12 Months, 24 Months, 36 Months</time_frame>
    <description>Major target limb amputation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Primary sustained clinical improvement</measure>
    <time_frame>6 Months, 12 Months, 24 Months, 36 Months</time_frame>
    <description>Primary sustained clinical improvement is defined as sustained upward shift of at least 1 category on Rutherford classification as compared to baseline without the need for repeated TLR or surgical revascularization in amputation-free surviving subjects</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Device Success</measure>
    <time_frame>Day 1</time_frame>
    <description>Device success is defined as successful delivery, balloon inflation and deflation and retrieval of the intact study device without burst below the rated burst pressure (RBP).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Procedural Success</measure>
    <time_frame>Day 1</time_frame>
    <description>Procedural success is defined as residual stenosis of ≤ 50% (non-stented subjects) or ≤ 30% (stented subjects) by visual estimate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Success</measure>
    <time_frame>Day 1</time_frame>
    <description>Clinical success is defined as procedural success without in hospital MALE and/or MACCE</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">512</enrollment>
  <condition>Peripheral Arterial Disease</condition>
  <condition>Superficial Femoral Artery Stenosis</condition>
  <condition>Iliac Artery Stenosis</condition>
  <condition>Arterial Occlusive Diseases</condition>
  <condition>Popliteal Artery Stenosis</condition>
  <condition>Critical Limb Ischemia</condition>
  <arm_group>
    <arm_group_label>Study Cohort</arm_group_label>
    <description>Subjects with symptoms of intermittent claudication and/or critical limb ischemia (Rutherford Class 2-3-4-5-6) with angiographic evidence of femoropopliteal-below-the-knee arterial occlusion or stenosis</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Drug Coated Balloon</intervention_name>
    <description>Legflow Drug Coated Balloon</description>
    <arm_group_label>Study Cohort</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Subjects with symptoms of intermittent claudication and/or critical limb ischemia
        (Rutherford Class 2-3-4-5-6) with angiographic evidence of femoropopliteal-below-the-knee
        iliac arterial occlusion or stenosis will be consecutively screened and enrolled based on
        the study inclusion and exclusion criteria.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Age ≥ 18 years or minimum age as required by local regulations.

          -  Subject with documented diagnosis of lower extremities arterial disease (LEAD).

          -  Angiographically documented single or multiple lesions/occlusions (de novo or
             re-stenotic lesion(s) or in-stent restenosis within the target vessels with a minimum
             lesion length of 2 cm including bilateral disease if both limbs are treated within 35
             days.

          -  Positive diagnostic indication for PTA with a DEB in accordance with the Instructions
             For Use (IFU) of the Legflow DEB.

          -  Adequate distal run-off to the ankle (at least one native calf vessel [posterior
             tibial, anterior tibial, or peroneal arteries] is patent, defined as ≤ 50% diameter
             stenosis) either pre-existing or successfully re- established prior to target lesion
             treatment.

          -  Adequate inflow (≤ 50% diameter stenosis) either pre-existing or successfully
             re-established prior to target lesion treatment.

          -  Female subjects of childbearing potential must have a negative pregnancy test ≤ 7 days
             before enrollment.

          -  Signed and dated Patient Informed Consent (PIC) form.

          -  Ability and willingness to comply with the clinical investigation plan (CIP).

          -  Life expectancy, in the Investigator's opinion, of at least 12 months

        Exclusion Criteria:

          -  High probability of non-adherence to CIP follow-up requirements.

          -  Failure to successfully cross the target lesion with a guide wire (successful crossing
             means tip of the guide wire distal to the target lesion in the absence of flow
             limiting dissections or perforations).

          -  Lesion within or adjacent to an aneurysm or presence of a popliteal aneurysm.

          -  Acute or sub-acute thrombus in the target vessel.

          -  Target lesion also requires treatment with alternative drug eluting technology-based
             therapy or other antiproliferative therapy (cryoplasty, brachytherapy).

          -  Plan for surgical or interventional procedure within 30 days after the study procedure
             (except for bilateral target limb treatment).

          -  Known allergies or sensitivities to heparin, aspirin, other anti-
             coagulant/anti-platelet therapies, and/or paclitaxel.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Eugenio Stabile, Prof.</last_name>
    <phone>+39 081 7462239</phone>
    <email>eugenio.stabile@unina.it</email>
  </overall_contact>
  <location>
    <facility>
      <name>Policlinico di Monza</name>
      <address>
        <city>Monza</city>
        <country>Italy</country>
      </address>
    </facility>
    <contact>
      <last_name>Giovanni Sorropago, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Università Federico II - Dipartimento Scienze Biomediche Avanzate</name>
      <address>
        <city>Napoli</city>
        <country>Italy</country>
      </address>
    </facility>
    <contact>
      <last_name>Eugenio Stabile, Prof.</last_name>
      <email>eugenio.stabile@unina.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Policlinico Umberto I</name>
      <address>
        <city>Roma</city>
        <country>Italy</country>
      </address>
    </facility>
    <contact>
      <last_name>Francesco Speziale, Prof.</last_name>
    </contact>
    <investigator>
      <last_name>Francesco Speziale, Prof</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Pasqualino Sirignano, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Angeles Mocel</name>
      <address>
        <city>Ciudad de Mexico</city>
        <country>Mexico</country>
      </address>
    </facility>
    <contact>
      <last_name>Alfonso Espinosa, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Lopez Mateos</name>
      <address>
        <city>Ciudad de Mexico</city>
        <country>Mexico</country>
      </address>
    </facility>
    <contact>
      <last_name>Jorge Torres, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Angeles del Carmen</name>
      <address>
        <city>Guadalajara</city>
        <country>Mexico</country>
      </address>
    </facility>
    <contact>
      <last_name>Gustavo Rubio, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Consulta Privada Cardiovascular Research Institute</name>
      <address>
        <city>Guadalajara</city>
        <country>Mexico</country>
      </address>
    </facility>
    <contact>
      <last_name>Luis Virgen, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Italy</country>
    <country>Mexico</country>
  </location_countries>
  <results_reference>
    <citation>Stabile E, Gerardi D, Magliulo F, Zhelev D, Chervenkoff V, Taeymans K, Kotasov D, Goverde P, Giugliano G, Trimarco B, Esposito G. One-Year Clinical Outcomes of the Legflow Drug-Coated Balloon for the Treatment of Femoropopliteal Occlusions Registry. J Endovasc Ther. 2019 Feb;26(1):26-30. doi: 10.1177/1526602818823557.</citation>
    <PMID>30760132</PMID>
  </results_reference>
  <verification_date>November 2019</verification_date>
  <study_first_submitted>November 12, 2019</study_first_submitted>
  <study_first_submitted_qc>November 21, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 22, 2019</study_first_posted>
  <last_update_submitted>November 21, 2019</last_update_submitted>
  <last_update_submitted_qc>November 21, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">November 22, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Federico II University</investigator_affiliation>
    <investigator_full_name>Eugenio Stabile</investigator_full_name>
    <investigator_title>Associate Professor of Cardiovascular Medicine</investigator_title>
  </responsible_party>
  <keyword>Stenosis</keyword>
  <keyword>Drug Coated Balloon</keyword>
  <keyword>Paclitaxel</keyword>
  <keyword>Artery Disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Peripheral Arterial Disease</mesh_term>
    <mesh_term>Peripheral Vascular Diseases</mesh_term>
    <mesh_term>Arterial Occlusive Diseases</mesh_term>
    <mesh_term>Constriction, Pathologic</mesh_term>
    <mesh_term>Ischemia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

